NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
After market 11:20:00 am | |||
| 867.5 DKK | -1.33% |
|
867.6 | +0.01% |
| Apr. 15 | More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm | RE |
| Apr. 15 | Biophytis: patent application filed in the field of obesity | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
879.2
DKK
Average target price
904.2
DKK
Spread / Average Target
+2.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.27% | 559B | |
| +27.77% | 676B | |
| -7.78% | 356B | |
| +15.10% | 320B | |
| +5.10% | 286B | |
| +2.62% | 213B | |
| +0.15% | 207B | |
| -9.41% | 199B | |
| -8.01% | 142B | |
| -3.31% | 116B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Reiterates Confidence in Once-weekly Insulin as New Late-stage Data Further Backs Drug's Potential
